	22101451D
1	HOUSE BILL NO. 921
2 3	Offered January 12, 2022
	Prefiled January 12, 2022
4 5	A BILL to amend and reenact § 54.1-3303 of the Code of Virginia, relating to prescribing of controlled substances; practitioner-patient relationship; telemedicine.
5 6	
Ŭ	Patron—Orrock
7	
8	Committee Referral Pending
9 10	Be it enacted by the General Assembly of Virginia:
11	1. That § 54.1-3303 of the Code of Virginia is amended and reenacted as follows:
12	§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic
13	purposes only.
14	A. A prescription for a controlled substance may be issued only by a practitioner of medicine,
15	osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled
16 17	substances, a licensed nurse practitioner pursuant to § 54.1-2957.01, a licensed certified midwife
17 18	pursuant to § 54.1-2957.04, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32.
19	B. A prescription shall be issued only to persons or animals with whom the practitioner has a bona
20	fide practitioner-patient relationship or veterinarian-client-patient relationship. If a practitioner is
21	providing expedited partner therapy consistent with the recommendations of the Centers for Disease
22	Control and Prevention, then a bona fide practitioner-patient relationship shall not be required.
23 24	A bona fide practitioner-patient relationship shall exist if the practitioner has (i) obtained or caused to be obtained a medical or drug history of the patient; (ii) provided information to the patient about the
25	benefits and risks of the drug being prescribed; (iii) performed or caused to be performed an appropriate
26	examination of the patient, either physically or by the use of instrumentation and diagnostic equipment
27	through which images and medical records may be transmitted electronically telemedicine, provided that
28	performance of such examination via telemedicine is consistent with the standard of care; and (iv)
29 30	initiated additional interventions and follow-up care, if necessary, especially if a prescribed drug may
30 31	have serious side effects. Except in cases involving a medical emergency, the examination required pursuant to clause (iii) shall be performed by the practitioner prescribing the controlled substance, a
32	practitioner who practices in the same group as the practitioner prescribing the controlled substance, or a
33	consulting practitioner.
34	A practitioner who has established a bona fide practitioner-patient relationship with a patient in
35 36	accordance with the provisions of this subsection may prescribe Schedule II through VI controlled substances to that patient.
30 37	A practitioner who has established a bona fide practitioner-patient relationship with a patient in
38	accordance with the provisions of this subsection may prescribe Schedule II through VI controlled
39	substances to that patient via telemedicine if, provided that such prescribing via telemedicine is in
40	compliance with state and federal requirements for the practice of prescribing of a controlled substance
41	via telemedicine and, in the case of the prescribing of a Schedule II through V controlled substance, the
42 43	prescriber maintains a practice at a physical location in the Commonwealth or is able to make appropriate referral of patients to a licensed practitioner located in the Commonwealth in order to ensure
4 4	an in-person examination of the patient when required by the standard of care.
45	A prescriber may establish a bona fide practitioner-patient relationship for the purpose of prescribing
46	Schedule II through $\forall I V$ controlled substances by an examination through face-to-face interactive,
47	two-way, real-time communications services or store-and forward technologies synchronous interaction
48 49	with the patient and may establish a bona fide practitioner-patient relationship for the purpose of prescribing Schedule VI controlled substances by an examination through asynchronous interaction with
49 50	the patient when all of the following conditions are met: (a) the patient has provided a medical history
51	that is available for review by the prescriber; (b) the prescriber obtains an updated medical history at the
52	time of prescribing; (c) the prescriber makes a diagnosis at the time of prescribing; (d) the prescriber
53	conforms to the standard of care expected of in-person care as appropriate to the patient's age and
54 55	presenting condition, including when the standard of care requires the use of diagnostic testing and
55 56	performance of a physical examination, which may be carried out through the use of peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the Commonwealth and
57	authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or carrier <i>and the</i>
58	patient has expressed an intent to seek reimbursement by the health plan or carrier for the encounter,

59 the prescriber has been credentialed by the health plan or carrier as a participating provider and the 60 diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier pursuant to § 38.2-3418.16; (g) upon request, the prescriber provides patient records in a timely manner 61 in accordance with the provisions of § 32.1-127.1:03 and all other state and federal laws and regulations; 62 63 (h) the establishment of a bona fide practitioner-patient relationship via telemedicine is consistent with 64 the standard of care, and the standard of care does not require an in-person examination for the purpose 65 of diagnosis; and (i) the establishment of a bona fide practitioner patient relationship via telemedicine is consistent with federal law and regulations and any waiver thereof. Nothing in this paragraph shall apply 66 to (1) a prescriber providing on-call coverage per an agreement with another prescriber or his 67 prescriber's professional entity or employer; (2) a prescriber consulting with another prescriber regarding 68 69 a patient's care; or (3) orders of prescribers for hospital out-patients or in-patients.

70 For purposes of this section, a bona fide veterinarian-client-patient relationship is one in which a 71 veterinarian, another veterinarian within the group in which he practices, or a veterinarian with whom he is consulting has assumed the responsibility for making medical judgments regarding the health of and 72 providing medical treatment to an animal as defined in § 3.2-6500, other than an equine as defined in 73 74 § 3.2-6200, a group of agricultural animals as defined in § 3.2-6500, or bees as defined in § 3.2-4400, 75 and a client who is the owner or other caretaker of the animal, group of agricultural animals, or bees has consented to such treatment and agreed to follow the instructions of the veterinarian. Evidence that a 76 77 veterinarian has assumed responsibility for making medical judgments regarding the health of and 78 providing medical treatment to an animal, group of agricultural animals, or bees shall include evidence 79 that the veterinarian (A) has sufficient knowledge of the animal, group of agricultural animals, or bees 80 to provide a general or preliminary diagnosis of the medical condition of the animal, group of 81 agricultural animals, or bees; (B) has made an examination of the animal, group of agricultural animals, or bees, either physically or by the use of instrumentation and diagnostic equipment through which 82 83 images and medical records may be transmitted electronically or has become familiar with the care and keeping of that species of animal or bee on the premises of the client, including other premises within 84 85 the same operation or production system of the client, through medically appropriate and timely visits to 86 the premises at which the animal, group of agricultural animals, or bees are kept; and (C) is available to 87 provide follow-up care.

As used in this subsection, (i) "asynchronous interaction" means an exchange of information between
a patient and a prescriber that does not occur in real time, (ii) "synchronous interaction" means an
exchange of information between a patient and a prescriber that occurs in real time, and (iii)
"telemedicine" means a method of delivering health care services through the use of telecommunications
or other technologies by a prescriber to a patient at a different physical location, including synchronous
and asynchronous interactions.

C. A prescription shall only be issued for a medicinal or therapeutic purpose in the usual course of treatment or for authorized research. A prescription not issued in the usual course of treatment or for authorized research is not a valid prescription. A practitioner who prescribes any controlled substance with the knowledge that the controlled substance will be used otherwise than for medicinal or therapeutic purposes shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the distribution or possession of controlled substances.

D. No prescription shall be filled unless a bona fide practitioner-patient-pharmacist relationship exists.
 A bona fide practitioner-patient-pharmacist relationship shall exist in cases in which a practitioner prescribes, and a pharmacist dispenses, controlled substances in good faith to a patient for a medicinal or therapeutic purpose within the course of his professional practice.

104 In cases in which it is not clear to a pharmacist that a bona fide practitioner-patient relationship 105 exists between a prescriber and a patient, a pharmacist shall contact the prescribing practitioner or his 106 agent and verify the identity of the patient and name and quantity of the drug prescribed.

107 Any person knowingly filling an invalid prescription shall be subject to the criminal penalties
 108 provided in § 18.2-248 for violations of the provisions of law relating to the sale, distribution or
 109 possession of controlled substances.

110 E. Notwithstanding any provision of law to the contrary and consistent with recommendations of the 111 Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe 112 Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient 113 when (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as defined in subsection B, with the diagnosed patient and (ii) in the practitioner's professional judgment, 114 115 the practitioner deems there is urgency to begin treatment to prevent the transmission of a communicable disease. In cases in which the practitioner is an employee of or contracted by the Department of Health 116 117 or a local health department, the bona fide practitioner-patient relationship with the diagnosed patient, as 118 required by clause (i), shall not be required.

F. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-statepractitioner of medicine, osteopathy, podiatry, dentistry, optometry, or veterinary medicine, a nurse

HB921

practitioner, or a physician assistant authorized to issue such prescription if the prescription complieswith the requirements of this chapter and the Drug Control Act (§ 54.1-3400 et seq.).

G. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to
\$ 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for controlled
substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
patient for a medicinal or therapeutic purpose within the scope of his professional practice.

H. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to
§ 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled
substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
patient for a medicinal or therapeutic purpose within the scope of his professional practice.

131 I. A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to 132 Article 5 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide 133 manufacturers' professional samples to his patients for medicinal or therapeutic purposes within the 134 scope of his professional practice for the drugs specified on the TPA-Formulary, established pursuant to § 54.1-3223, which shall be limited to (i) analgesics included on Schedule II controlled substances as 135 136 defined in § 54.1-3448 of the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in combination with acetaminophen; (ii) oral analgesics included in Schedules III through VI, as defined in 137 138 §§ 54.1-3450 and 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.), which are appropriate to 139 relieve ocular pain; (iii) other oral Schedule VI controlled substances, as defined in § 54.1-3455 of the 140 Drug Control Act, appropriate to treat diseases and abnormal conditions of the human eye and its 141 adnexa; (iv) topically applied Schedule VI drugs, as defined in § 54.1-3455 of the Drug Control Act; 142 and (v) intramuscular administration of epinephrine for treatment of emergency cases of anaphylactic 143 shock.

J. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by
 a member or committee of a hospital's medical staff when approving a standing order or protocol for the
 administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with
 § 32.1-126.4.

148 K. Notwithstanding any other provision of law, a prescriber may authorize a registered nurse or 149 licensed practical nurse to approve additional refills of a prescribed drug for no more than 90 150 consecutive days, provided that (i) the drug is classified as a Schedule VI drug; (ii) there are no changes in the prescribed drug, strength, or dosage; (iii) the prescriber has a current written protocol, accessible 151 by the nurse, that identifies the conditions under which the nurse may approve additional refills; and (iv) 152 153 the nurse documents in the patient's chart any refills authorized for a specific patient pursuant to the 154 protocol and the additional refills are transmitted to a pharmacist in accordance with the allowances for 155 an authorized agent to transmit a prescription orally or by facsimile pursuant to subsection C of § 156 54.1-3408.01 and regulations of the Board.